# Aldo P. Maggioni

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/aldo-p-maggioni/

## Facts

| Field | Value |
| --- | --- |
| Citations | 130,502 |
| Field | Heart Failure Treatment and Management |
| h-index | 157 |
| i10-index | 831 |
| Last Known Institution | Associazione Nazionale Medici Cardiologi Ospedalieri |
| OpenAlex ID | https://openalex.org/A5088186128 |
| ORCID iD | 0000-0003-2764-6779 |
| Works | 1,593 |

## Researcher papers

Showing 12 of 44.

- [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC](https://scholariq.org/papers/esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-2/)
- [Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)](https://scholariq.org/papers/guidelines-for-the-diagnosis-and-treatment-of-pulmonary-hypertension-the-task/)
- [Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction](https://scholariq.org/papers/efficacy-and-safety-of-low-dose-colchicine-after-myocardial-infarction/)
- [ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012](https://scholariq.org/papers/esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-4/)
- [Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both](https://scholariq.org/papers/valsartan-captopril-or-both-in-myocardial-infarction-complicated-by-heart/)
- [Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials](https://scholariq.org/papers/statins-and-risk-of-incident-diabetes-a-collaborative-meta-analysis-of/)
- [Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-stable-cardiovascular-disease/)
- [Initial Invasive or Conservative Strategy for Stable Coronary Disease](https://scholariq.org/papers/initial-invasive-or-conservative-strategy-for-stable-coronary-disease/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome](https://scholariq.org/papers/lixisenatide-in-patients-with-type-2-diabetes-and-acute-coronary-syndrome/)
- [Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/effects-of-once-weekly-exenatide-on-cardiovascular-outcomes-in-type-2-diabetes/)
- [The Seattle Heart Failure Model](https://scholariq.org/papers/the-seattle-heart-failure-model/)

## Researcher topics

- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Cardiac pacing and defibrillation studies](https://scholariq.org/topics/cardiac-pacing-and-defibrillation-studies/)

## Researcher university

- [Associazione Nazionale Medici Cardiologi Ospedalieri](https://scholariq.org/institutions/associazione-nazionale-medici-cardiologi-ospedalieri/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.